Hangzhou Hezekunyuan Pharmaceutical Co., Ltd.

The main purpose of the study is to study the pharmacokinetics of the test preparation brepirazole tablets (specification: 2 mg, developed by Hangzhou Heze Kunyuan Pharmaceutical Co., Ltd.) and the reference preparation brepirazole tablets (REXULTI®, specification: 2 mg, certified by Otsuka Pharmaceutical Co., Ltd) in healthy subjects after a single oral administration under fasting conditions, and to evaluate the bioequivalence of the two preparations after oral administration under fasting conditions. Secondary purpose of the study is to evaluate the safety of the test preparation and reference preparation of brepirazole tablets after a single oral administration under fasting conditions in healthy subjects.

To investigate the pharmacokinetic behavior of the test formulation of ilaprazole enteric-coated tablets and the reference formulation of ilaprazole enteric-coated tablets (Ilian®) in healthy Chinese subjects after single oral administration on an empty stomach or after a meal, and to evaluate the bioequivalence of the two formulations after oral administration on an empty stomach or after a meal. To evaluate the safety of the test formulation of ilaprazole enteric-coated tablets and the reference formulation of ilaprazole enteric-coated tablets (Ilian®) in healthy Chinese subjects after single oral administration on an empty stomach or after a meal.

To investigate the pharmacokinetic behavior of the test formulation of ilaprazole enteric-coated tablets and the reference formulation of ilaprazole enteric-coated tablets (Ilian®) in healthy Chinese subjects after a single oral administration, and to evaluate the bioequivalence of the two formulations after fasting and postprandial oral administration. To evaluate the safety of the test formulation of ilaprazole enteric-coated tablets and the reference formulation of ilaprazole enteric-coated tablets (Ilian®) in healthy Chinese subjects after a single oral administration.